PhRMA

America’s leadership in medicine development matters. America has delivered lifesaving breakthroughs and fueled economic opportunity nationwide. For the first time in decades, America’s spot as a global leader is on the line. Learn how smart policies can keep us in the lead:

Artificial intelligence is reshaping how medicines are discovered, developed and delivered. Read more about how AI is transforming the drug innovation lifecycle: phrma.org/blog/how-ai-is…

At PhRMA Forum, Former FDA Commissioner Scott Gottlieb outlined the all-of-government response needed to keep our competitive edge against China in medical innovation.

Nearly half of Medicare Part D beneficiaries faced a coverage denial when starting a brand medicine, according to a new IQVIA analysis. Coverage on paper isn’t accessible in practice. phrma.org/blog/insurers-…

Half of what’s spent on brand medicines goes to entities that did not make them. Middlemen negotiate significant rebates and discounts with the biopharmaceutical companies, but those savings do not always reach patients at the pharmacy counter. Addressing how rebates and discounts flow through the system and increasing transparency will help patients.

340B medicine markups are a pot of gold for big hospitals. And with no rules on how program profits are used, many hospitals are using that money in egregious ways, with no evidence that patients are benefiting.  So, if patients aren’t benefiting, where’s the money going?

MFN imports more than foreign prices—it imports foreign rationing formulas. By tying U.S. prices to QALY‑based systems, MFN risks importing value judgments that disadvantage people with disabilities and chronic illness. Affordability should expand access, not ration care. phrma.org/blog/mfn-drug-…

America’s innovation ecosystem delivers real advantages. 87% of new medicines are available in the U.S., often within months. Protecting the policies that support innovation helps ensure the next generation of cures is discovered here. washingtonpost.com/creativegroup/…

America’s biopharma leadership is on the line. China’s biotech investments now allow them to: 📊 Run Phase I trials 50% faster and 40% cheaper than the U.S. 📈 Conduct 30% of global clinical trials, up from 5% a decade ago. We must protect America’s innovative edge.

Behind every breakthrough is a patient waiting for hope. National MPS Society President @terrilklein shares how her daughter’s rare disease diagnosis changed everything. Science has delivered important progress, but families are still waiting for treatments.

We are entering an important moment for this industry – and America must choose to lead in biopharmaceutical innovation. It’s about the next generation of cures. It’s about access to medicines for patients. It’s about who we are as Americans.

Price setting policies like MFN aren’t the right prescription for American patients. Read more: phrma.org/blog/leadershi…

While China steps on the gas, the U.S. steps on the brakes. Former FDA Commissioner Scott Gottlieb makes the case that innovation reflects values, and we must value and prioritize innovation or be left behind and vulnerable.

What you need to know: new data shows big, tax-exempt hospital markups are sometimes more than 10,000% of estimated acquisition costs at 340B hospitals. Read the report ⬇️ phrma.org/blog/340b-hosp…

New analysis from Avalere Health highlights the increasing commercial health plan use of AAPs, copay maximizers, and AFPs. Read more here: advisory.avalerehealth.com/wp-content/upl…

Biopharmaceutical industry investments drive the fastest access to breakthrough treatments and economic benefits in every state. Since 2015, there has been a 69% growth in U.S. pharma exports.

DYK: 2/3 of the medicines consumed in the U.S. are made in the U.S. America’s leadership in biopharmaceutical innovation means a healthier and more secure America. Read more:

There have been some big recent wins to crack down on middlemen and bring affordability and transparency to patients. Congress passed a bipartisan law on misaligned incentives. The FTC reached a landmark PBM settlement requiring transparency and lower net prices. DOL called for commercial market transparency. More work remains.

America’s leadership in medicine development drives jobs, investment and growth nationwide. 5M+ jobs. $500B in new investments. $1.2T in economic impact.

A new Minnesota report shows 340B participants in the state generated $1.34 billion in 340B net revenue in a single year, yet there’s no guardrails or transparency on how program profits are used or whether patients benefit. phrma.org/blog/new-repor…

Big news from @CSL: a new $1.5 billion expansion of its manufacturing facility in Kankakee, Illinois to build on their $3 billion investment since 2018. The project will expand production of plasma-derived therapies and create 300 new jobs. newsroom.csl.com/2026-03-09-CSL…